SEC Form 4 · accession 0001179110-15-014428
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Martin
Officer — Chairman and CEO · Director
Period of report
Nov 2, 2015
Accepted (ET)
Nov 4, 2015 · 1:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2015 | M | 150,000 | $14.5025 | A | 4,098,066 | D | |
| Common StockF3 | Nov 2, 2015 | S | 42,417 | $109.0176 | D | 4,055,649 | D | |
| Common StockF4 | Nov 2, 2015 | S | 107,583 | $109.5789 | D | 3,948,066 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock option (right to buy)F2 | $14.5025 | Nov 2, 2015 | M | 150,000 | D | — | Jan 25, 2016 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $108.40 to $109.40. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $109.41 to $109.93. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.